Lipid-based nanovesicles for nanomedicine

被引:232
|
作者
Grimaldi, N. [1 ,2 ]
Andrade, F. [1 ,3 ]
Segovia, N. [1 ,3 ]
Ferrer-Tasies, L. [1 ,3 ]
Sala, S. [1 ,3 ]
Veciana, J. [1 ,3 ]
Ventosa, N. [1 ,3 ]
机构
[1] Campus Univ Bellaterra, Inst Ciencia Mat Barcelona ICMAB CSIC, Cerdanyola Del Valles 08193, Spain
[2] Campus Univ Bellaterra, Nanomol Technol SA, Modul Recerca B, Cerdanyola Del Valles 08193, Spain
[3] CIBER BBN, Madrid, Spain
关键词
NONIONIC SURFACTANT VESICLES; LARGE UNILAMELLAR VESICLES; ULTRADEFORMABLE DRUG CARRIERS; ENHANCED TRANSDERMAL DELIVERY; IN-VITRO CHARACTERIZATION; PH-SENSITIVE LIPOSOMES; TARGETED DELIVERY; TOPICAL DELIVERY; OCULAR DELIVERY; PHYSICOCHEMICAL PROPERTIES;
D O I
10.1039/c6cs00409a
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Molecular self-assembly has enabled the fabrication of biologically inspired, advanced nanostructures as lipid-based nanovesicles (L-NVs). The oldest L-NVs, liposomes, have been widely proposed as potential candidates for drug delivery, diagnostic and/or theranostic applications and some liposome-based drug products have already stepped from the lab-bench to the market. This success is attributed to their ability to encapsulate both hydrophobic and/or hydrophilic molecules, efficiently carry and protect them within the body and finally deliver them at the target site. These positive features are also coupled with high biocompatibility. However, liposomes still present some unsolved drawbacks, such as poor colloidal stability, short shelf-life, restricted and expensive conditions of preparation because of the inherent nature of their fundamental constituents (phospholipids). The new tools available in the self-assembly of controlled molecules have significantly advanced the field of L-NV design and synthesis, and non-liposomal L-NVs have been recently developed; this new generation of nanovesicles can represent a paradigm shift in nanomedicine: they may complement liposomes, showing their advantages and overcoming most of their drawbacks. Clearly, being still young, their rocky way to the clinic first and then to the market has just started and it is still long, but they have all the potentialities to reach their objective target. The purpose of this review is to first present the large plethora of L-NVs available, focusing on this new generation of non-liposomal L-NVs and showing their similarities and differences with respect to their ancestors (liposomes). Since the overspread of a nanomaterial to the market is also strongly dependent on the availability of technological-scale preparation methods, we will also extensively review the current approaches exploited for L-NV production. The most cutting-edge approaches based on compressed fluid (CF) technologies will be highlighted here since they show the potential to represent a game-change in the production of L-NVs, favouring their step from the bench to the market. Finally, we will briefly discuss L-NV applications in nanomedicine, looking also for their future perspectives.
引用
收藏
页码:6520 / 6545
页数:26
相关论文
共 50 条
  • [21] Lipid-Based Nanotechnology: Liposome
    Jiang, Yanhao
    Li, Wenpan
    Wang, Zhiren
    Lu, Jianqin
    PHARMACEUTICS, 2024, 16 (01)
  • [22] LIPID-BASED TUBULE MICROSTRUCTURES
    SCHNUR, JM
    PRICE, R
    SCHOEN, P
    YAGER, P
    CALVERT, JM
    GEORGER, J
    SINGH, A
    THIN SOLID FILMS, 1987, 152 (1-2) : 181 - 206
  • [23] Nanomedicine Strategies Utilizing Lipid-Based Nanoparticles for Liver Cancer Therapy: Exploring Signaling Pathways and Therapeutic Modalities
    Asgharzadeh, Fereshteh
    Binabaj, Maryam Moradi
    Fanoudi, Sahar
    Cho, William C.
    Yang, Yu-jeong
    Azarian, Maryam
    Ardestani, Mehdi Shafiee
    Nasiri, Nasim
    Farani, Marzieh Ramezani
    Huh, Yun Suk
    ADVANCED PHARMACEUTICAL BULLETIN, 2024, 14 (03) : 513 - 523
  • [24] Going skin deep: A direct comparison of penetration potential of lipid-based nanovesicles on the isolated perfused human skin flap model
    Ternullo, Selenia
    de Weerd, Louis
    Holsaeter, Ann Mari
    Flaten, Goril Eide
    Skalko-Basnet, Natasa
    EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, 2017, 121 : 14 - 23
  • [25] Lipid-based signalling in Chlamydomonas gametes
    Musgrave, A.
    Munnik, T.
    van Himbergen, J.
    Meijer, H.
    Kuin, H.
    Koerten, H.
    Cambier, P.
    PHYCOLOGIA, 1997, 36 (04) : 76 - 76
  • [26] Cancer Chemotherapy With Lipid-Based Nanocarriers
    Liu, Donghua
    Zhang, Na
    CRITICAL REVIEWS IN THERAPEUTIC DRUG CARRIER SYSTEMS, 2010, 27 (05): : 371 - 417
  • [27] Lipid-Based Nanocarriers for The Treatment of Glioblastoma
    Iturrioz-Rodriguez, Nerea
    Bertorelli, Rosalia
    Ciofani, Gianni
    ADVANCED NANOBIOMED RESEARCH, 2021, 1 (02):
  • [28] Lipid-based therapeutics: a different approach
    Robinson, C
    DRUG DISCOVERY TODAY, 1997, 2 (11) : 449 - 450
  • [29] Lipid-Based Nanocarriers for Lymphatic Transportation
    Vishwakarma, Nikhar
    Jain, Anamika
    Sharma, Rajeev
    Mody, Nishi
    Vyas, Sonal
    Vyas, Suresh P.
    AAPS PHARMSCITECH, 2019, 20 (02)
  • [30] Lipid-based siRNA Delivery Systems
    Dong Wen-Juan
    Zhou Yin-Jian
    Liang Wei
    PROGRESS IN BIOCHEMISTRY AND BIOPHYSICS, 2012, 39 (05) : 396 - 401